Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide once weekly versus placebo for gastric emptying and postprandial responses in type 2 diabetes
ACTRN12624000570583Phase 2Recruiting
- Sponsor
- University of Adelaide
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide once weekly with Placebo once weekly (2 arms). Primary endpoint: Gastric emptying AUC0-180min. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12624000570583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000570583.